Strs Ohio cut its stake in shares of Boston Scientific Co. (NYSE:BSX) by 4.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 723,409 shares of the medical equipment provider’s stock after selling 37,404 shares during the quarter. Strs Ohio owned 0.05% of Boston Scientific worth $23,655,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of BSX. Kaizen Advisory LLC lifted its holdings in shares of Boston Scientific by 146.7% during the second quarter. Kaizen Advisory LLC now owns 3,299 shares of the medical equipment provider’s stock worth $108,000 after purchasing an additional 1,962 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of Boston Scientific by 3,090.5% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,020 shares of the medical equipment provider’s stock worth $131,000 after purchasing an additional 3,894 shares during the period. Ostrum Asset Management acquired a new stake in shares of Boston Scientific during the first quarter worth $174,000. Summit Trail Advisors LLC lifted its holdings in shares of Boston Scientific by 3,853.8% during the first quarter. Summit Trail Advisors LLC now owns 194,923 shares of the medical equipment provider’s stock worth $195,000 after purchasing an additional 189,993 shares during the period. Finally, Alps Advisors Inc. acquired a new stake in shares of Boston Scientific during the first quarter worth $200,000. 88.92% of the stock is owned by hedge funds and other institutional investors.

In other news, EVP David A. Pierce sold 5,000 shares of the firm’s stock in a transaction on Friday, June 1st. The stock was sold at an average price of $30.58, for a total value of $152,900.00. Following the completion of the transaction, the executive vice president now owns 29,201 shares in the company, valued at $892,966.58. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Kevin J. Ballinger sold 68,486 shares of the firm’s stock in a transaction on Monday, June 11th. The shares were sold at an average price of $34.12, for a total value of $2,336,742.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 138,043 shares of company stock valued at $4,643,533. Company insiders own 0.73% of the company’s stock.

BSX has been the subject of several research analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $36.00 price objective on shares of Boston Scientific in a research report on Wednesday, April 25th. JPMorgan Chase & Co. increased their price objective on Boston Scientific from $31.00 to $32.00 and gave the stock an “overweight” rating in a research report on Thursday, April 26th. Leerink Swann increased their price objective on Boston Scientific from $32.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, April 26th. Needham & Company LLC increased their price objective on Boston Scientific from $35.00 to $36.00 and gave the stock a “strong-buy” rating in a research report on Thursday, April 26th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $31.00 price objective on shares of Boston Scientific in a research report on Thursday, April 26th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $34.95.

Shares of BSX stock opened at $34.29 on Friday. Boston Scientific Co. has a fifty-two week low of $24.54 and a fifty-two week high of $37.30. The firm has a market capitalization of $46.40 billion, a PE ratio of 27.21, a PEG ratio of 2.45 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.83 and a quick ratio of 0.60.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 25th. The medical equipment provider reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.07. Boston Scientific had a return on equity of 26.35% and a net margin of 5.48%. The business had revenue of $2.49 billion during the quarter, compared to analysts’ expectations of $2.47 billion. During the same quarter last year, the business posted $0.32 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. sell-side analysts anticipate that Boston Scientific Co. will post 1.38 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Story: How to Invest in Marijuana Stocks

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.